Cover Image
市場調查報告書

腎上腺腦白質營養不良:開發中產品分析

Adrenoleukodystrophy - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361622
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺腦白質營養不良:開發中產品分析 Adrenoleukodystrophy - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 61 Pages
簡介

腎上腺腦白質營養不良是男性最常發生的疾病。主要影響位於每個腎臟頂部的小腺體之神經系統和腎上腺。Abetalipoproteinemia也是一種腎上腺腦白質營養不良(腎上腺皮質神經病/Schilder-Addison Complex)Bassen-Kornzweig症候群是一種罕見的疾病,是易於家族內發病,無法充分吸收膳食脂肪的腸道所引起。這種疾病是由於基因缺陷命令身體產生脂蛋白所造成。症狀有隨時間造成脊柱彎曲,肌肉無力,視力降低等。治療可使用大劑量含有脂溶性維生素的維生素補充劑。

本報告提供腎上腺腦白質營養不良的治療藥開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腎上腺腦白質營養不良概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • bluebird bio Inc
  • MedDay SA
  • Minoryx Therapeutics sl
  • Pfizer Inc
  • ReceptoPharm Inc
  • Viking Therapeutics Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9317IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2017, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.

Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview
    • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development
    • bluebird bio Inc
    • MedDay SA
    • Minoryx Therapeutics sl
    • Pfizer Inc
    • ReceptoPharm Inc
    • Viking Therapeutics Inc
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles
    • biotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DRX-065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUOC-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lenti-D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGTA-456 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIN-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pioglitazone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPI-78M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temsirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VK-0214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VK-2809 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 21, 2017: Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102
      • Feb 22, 2017: Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102
      • Jan 18, 2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB)
      • Dec 14, 2016: Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102
      • Dec 06, 2016: Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
      • Sep 26, 2016: Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 86th Annual Meeting of the American Thyroid Association
      • Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016
      • Jul 26, 2016: Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
      • Jul 06, 2016: Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102
      • Jun 14, 2016: Minoryx Therapeutics appoints Dr. Uwe Meya as Chief Medical Officer
      • Apr 03, 2014: Minoryx receives Orphan Drug Designation for MIN-101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Applied Genetic Technologies Corp, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by bluebird bio Inc, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by MedDay SA, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Minoryx Therapeutics sl, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Pfizer Inc, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by ReceptoPharm Inc, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline by Viking Therapeutics Inc, H1 2017
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top